Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

類似資料

• Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore
  著者:: Harenberg, Anke, 等
  出版事項: (2013)
• Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series
  著者:: Park, Juliana, 等
  出版事項: (2019)
• Evaluation of the viability and functionality of human peripheral blood mononuclear cells cryopreserved up to 2 years in animal-protein-free freezing media compared to the FBS-supplemented reference medium
  著者:: Frédérique Jantet-Blaudez, 等
  出版事項: (2025-08-01)
• Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: Phase II randomized controlled trial in Singapore
  著者:: Sin Leo, Yee, 等
  出版事項: (2012)
• Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
  著者:: Tran, Ngoc Huu, 等
  出版事項: (2019)